Systems pharmacology for drug discovery and development: Paradigm shift or flash in the pan?

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 379-381

  Vicini, P ^a   Van Der Graaf, P H ^b,c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; HUMAN; INFORMATION PROCESSING; PRIORITY JOURNAL; PROCEDURES; QUANTITATIVE ANALYSIS; REVIEW; SIMULATION; SYSTEMS PHARMACOLOGY;

ANIMALS; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 84876567464     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.40     Document Type: Review

References (11)

1. Iyengar, R., Zhao, S., Chung, S.-W., Mager, D.E. & Gallo, J.M. Merging systems biology with pharmacodynamics. Sci. Transl. Med. 4, 126ps7 (2012).
2. Van der Graaf, P.H. CPT: Pharmacometrics and Systems Pharmacology. CPT: Pharmacomet. Syst. Pharmacol. 1, e8 (2012).
3. Goldenfeld, N. & Kadanoff, L.P. Viewpoint: simple lessons from complexity. Science 284, 87-89 (1999).
4. Sorger, P.K. et al. Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH white paper by the QSP Workshop Group 〈http://www.nigms.nih.gov/nr/rdonlyres/8ecb1f7c-be3b-431f-89e6- a43411811ab1/0/systemspharmawpsorger2011.pdf〉 (October 2011).
5. Kohl, P. & Noble, D. Systems biology and the virtual physiological human. Mol. Syst. Biol. 5, 292 (2009).
6. Lippert, J. et al. A mechanistic, model-based approach to safety assessment in clinical development. CPT: Pharmacomet. Syst. Pharmacol. 1, e13 (2012).
7. Geerts, H., Spiros, A., Roberts, P. & Carr, R. Has the time come for predictive computer modeling in CNS drug discovery and development? CPT: Pharmacomet. Syst. Pharmacol. 1, e16 (2012).
8. Hendriks, B.S. et al. Multiscale kinetic modeling of liposomal doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors. CPT: Pharmacomet. Syst. Pharmacol. 1, e15 (2012).
9. Peterson, M.C. & Riggs, M.M. Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model. CPT: Pharmacomet. Syst. Pharmacol. 1, e14 (2012).
10. Riggs, M.M., Bennetts, M., van der Graaf, P.H. & Martin, S.W. Integrated pharmacometrics and systems pharmacology model-based analyses to guide GnRH receptor modulator development for management of endometriosis. CPT: Pharmacomet. Syst. Pharmacol. 1, e11 (2012).
11. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov. Today 17, 419-424 (2012).